Bernstein’s longtime Big Pharma analyst Tim Anderson is headed to a new research firm that’s been attracting some attention recently.
Anderson left Bernstein recently and is headed to Wolfe Research, where he will begin in September. The website cites their coverage of “about 36 sub-sectors through 15 senior research analysts,” along with a 2016 and 2017 win as a top 15 group — by Institutional Investor.
The scuttlebutt around the analyst community is that Wolfe now wants to build the next Bernstein. And Anderson tells me via LinkedIn that he’s looking forward to the move, noting:
Yes, I am moving on. Fundamentals are tough on the sell-side, but the place I am going to (Wolfe Research) has managed to find itself in the sweet spot where they are gaining share, and are able to grow the business at a time when many others others are having to contract. Good to be in growth mode! I will not officially emerge at Wolfe until late September.
Of all the Big Pharma analysts, Anderson always seemed to most relish the deep dive report into the companies he covered. And he had remarkable access, recently sitting down recently with Roche CEO Severin Schwan and reviewing the company’s R&D strategy, along with the possible integration of pRED and gRED (“over my dead body”).
A longtime observer of Merck, Anderson has also provided some significant cheerleading for their Keytruda pipeline, noting its advantages over Bristol-Myers Squibb which recently shoved Merck into the frontrunner position in terms of overall revenue — as well as overall survival.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.Free Subscription